- ICH GCP
- US Clinical Trials Registry
- Clinical Trial NCT01265797
Cranial Electrotherapy Stimulation in the Treatment of Migraine Headaches
February 2, 2015 updated by: Gretchen Tietjen, MD, University of Toledo Health Science Campus
Cranial electrotherapy stimulation (CES) may be a safe adjunct to medical treatment for pain relief in migraine patients.
However, despite the number of CES studies done, many have been open label, single blinded, or have utilized a small group of patients.
Study Overview
Status
Completed
Conditions
Intervention / Treatment
Detailed Description
This study will evaluate the efficacy of the Fisher Wallace Cranial Stimulator in persons with chronic migraine who have not achieved satisfactory pain control on their current medications.
Study Type
Interventional
Enrollment (Actual)
68
Phase
- Not Applicable
Contacts and Locations
This section provides the contact details for those conducting the study, and information on where this study is being conducted.
Study Locations
-
-
Ohio
-
Toledo, Ohio, United States, 43614
- University of Toledo, Health Science Campus
-
-
Participation Criteria
Researchers look for people who fit a certain description, called eligibility criteria. Some examples of these criteria are a person's general health condition or prior treatments.
Eligibility Criteria
Ages Eligible for Study
16 years to 63 years (Adult, Older Adult)
Accepts Healthy Volunteers
No
Genders Eligible for Study
All
Description
Inclusion Criteria:
- Subjects satisfying the IHS (International Headache Society) criteria for migraine
- Subjects have not achieved satisfactory pain control on their current medication
- Ability to maintain a daily headache diary
- Stable medication use related to migraine for at least 4 weeks prior to enrollment in the study
Exclusion Criteria:
- Previous exposure to or experience with cranial electrotherapy stimulation (CES)
- Contraindications to Fisher Wallace stimulator, such as cardiac pacemakers or implantable defibrillators, known or suspected heart disease, or pregnancy
- Seizure disorders
Study Plan
This section provides details of the study plan, including how the study is designed and what the study is measuring.
How is the study designed?
Design Details
- Primary Purpose: Treatment
- Allocation: Randomized
- Interventional Model: Parallel Assignment
- Masking: Double
Arms and Interventions
Participant Group / Arm |
Intervention / Treatment |
---|---|
Active Comparator: Cranial Electrostimulator
wears active cranial electrostimulation device for 20 minutes daily for 28 days
|
participant wears active cranial electrostimulation device for 20 minutes daily for 28 days
Other Names:
|
Sham Comparator: Sham device
wears sham device for 20 minutes daily for 28 days
|
participant wears sham device for 20 minutes daily for 28 days
|
What is the study measuring?
Primary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
---|---|---|
Mean Headache Days
Time Frame: 28 day period during run-in month and blinded month
|
Mean change in headache days between 28 day run-in month and 28 day blinded month, i.e. run-in month mean minus blinded month mean.
A good response is >= 50% reduction in headache days (congruent with the Guidelines for Trial of Behavioral Treatments for Recurrent Headache).
|
28 day period during run-in month and blinded month
|
Depression Score (PATIENT HEALTH QUESTIONNAIRE [PHQ] 9)
Time Frame: 14 days recall; measured at end of run-in month and blinded month
|
Mean difference of PHQ-9 score between the run-in month and blinded month, i.e.
PHQ-9 score from run-in month minus blinded month.
The PHQ-9 is a tool for assisting in diagnosing depression (over the prior 2 week period) as well as selecting and monitoring treatment.
There are nine items, with responses each ranging from 0 (not at all) to 3 (nearly every day), for a total range of 0 to 27.
The higher the total the more severe the depressive symptoms.
|
14 days recall; measured at end of run-in month and blinded month
|
Secondary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
---|---|---|
Headache Days
Time Frame: 28 day period in run-in month and open label month
|
Mean change in headache days between 28 day run-in month and 28 day open label month, i.e. run-in month mean minus open label month mean.
A good response is >= 50% reduction in headache days (congruent with the Guidelines for Trial of Behavioral Treatments for Recurrent Headache).
|
28 day period in run-in month and open label month
|
Depression Score (Patient Health Questionnaire-9)
Time Frame: 14 day recall, recorded at the end of run-in and open label months
|
Mean difference of PHQ-9 score between the run-in month and open label month, i.e.
PHQ-9 score from run-in month minus open label month.
The PHQ-9 is a tool for assisting in diagnosing depression (over the prior 2 week period) as well as selecting and monitoring treatment.
There are nine items, with responses each ranging from 0 (not at all) to 3 (nearly every day), for a total range of 0 to 27.
The higher the total the more severe the depressive symptoms.
|
14 day recall, recorded at the end of run-in and open label months
|
Headache Impact Test-6
Time Frame: after run-in month, after blinded month
|
Mean difference in HIT-6 score between run-in month and blinded month.
The HIT-6 is a tool for screening and monitoring change in headache disability.
This disease-specific health survey is intended for adults 18 years of age and older, and is available with a standard four-week recall period.
It is a 6 item questionnaire with scores for each item ranging from 6 (never) to 13 (always).
The minimum overall score is 36 and the maximum is 78.
Higher scores represent greater disability.
|
after run-in month, after blinded month
|
Headache Impact Test (HIT-6) (Measure of Disability Due to Headaches)
Time Frame: 28 day period in run-in month and open label month
|
Mean difference in HIT-6 score between run-in month and open label month.
The HIT-6 is a tool for screening and monitoring change in headache disability.
This disease-specific health survey is intended for adults 18 years of age and older, and is available with a standard four-week recall period.
It is a 6 item questionnaire with scores for each item ranging from 6 (never) to 13 (always).
The minimum overall score is 36 and the maximum is 78.
Higher scores represent greater disability.
|
28 day period in run-in month and open label month
|
Generalized Anxiety Disorder Score (GAD 7)
Time Frame: 14 days recall; measured at end of run-in month and blinded month
|
Mean difference in GAD 7 score between run-in month and blinded month.
This is a screening tool and severity measure for generalized anxiety disorder addressing symptoms over the prior 2 weeks.
It is a 7 item questionnaire with response scores for each item ranging from 0 (not at all) to 3 (every day).
The range for the total score is 0 to 21, with higher scores representing greater symptoms of anxiety
|
14 days recall; measured at end of run-in month and blinded month
|
Generalized Anxiety Disorder Score (GAD 7)
Time Frame: 14 day recall, recorded at the end of run-in and open label months
|
Mean difference in GAD 7 score between run-in month and open label month.
This is a screening tool and severity measure for generalized anxiety disorder addressing symptoms over the prior 2 weeks.
It is a 7 item questionnaire with response scores for each item ranging from 0 (not at all) to 3 (every day).
The range for the total score is 0 to 21, with higher scores representing greater symptoms of anxiety
|
14 day recall, recorded at the end of run-in and open label months
|
Somatic Symptom Severity (Patient Health Questionnaire 15)
Time Frame: 28 days recall; measured at end of run-in month and blinded month
|
Mean difference in PHQ 15 score between run-in month and blinded month.
The PHQ-15 comprises 15 somatic symptoms experienced over the prior 4 weeks and their severity, each symptom scored from 0 ("not bothered at all") to 2 ("bothered a lot").
The range for the overall score is between 0 and 30, with higher score representing more severe somatic symptoms
|
28 days recall; measured at end of run-in month and blinded month
|
Somatic Symptom Score (Patient Health Questionnaire-15)
Time Frame: 28 day period in run-in month and open label month
|
Mean difference in PHQ 15 score between run-in month and open label month.
The PHQ-15 comprises 15 somatic symptoms experienced over the prior 4 weeks and their severity, each symptom scored from 0 ("not bothered at all") to 2 ("bothered a lot").
The range for the overall score is between 0 and 30, with higher score representing more severe somatic symptoms.
|
28 day period in run-in month and open label month
|
Epworth Sleepiness Scale Score
Time Frame: recorded at the end of run-in month and blinded month
|
Mean difference of Epworth Sleepiness Scale score between run-in month and blinded month.
The Epworth Sleepiness Scale is used to measure excessive daytime sleepiness.
This is an 8 item questionnaire, recalling probability of falling asleep in "recent times".
The subjects are asked to rate probability of falling asleep in eight different situations.
The score for each item ranges from 0 (would never doze) to 3 (high chance of dozing), with the overall score range of 0 to 24.
Higher scores represent higher probability of falling asleep.
|
recorded at the end of run-in month and blinded month
|
Epworth Sleepiness Scale Score
Time Frame: Score recorded at the end of run-in and open label month
|
Mean difference of Epworth Sleepiness Scale score between run-in month and open label month.
The Epworth Sleepiness Scale is used to measure excessive daytime sleepiness.
This is an 8 item questionnaire, recalling probability of falling asleep in "recent times".
The subjects are asked to rate probability of falling asleep in eight different situations.
The score for each item ranges from 0 (would never doze) to 3 (high chance of dozing), with the overall score range of 0 to 24.
Higher scores represent higher probability of falling asleep.
|
Score recorded at the end of run-in and open label month
|
Collaborators and Investigators
This is where you will find people and organizations involved with this study.
Investigators
- Principal Investigator: Gretchen Tietjen, MD, University of Toledo, HSC
Study record dates
These dates track the progress of study record and summary results submissions to ClinicalTrials.gov. Study records and reported results are reviewed by the National Library of Medicine (NLM) to make sure they meet specific quality control standards before being posted on the public website.
Study Major Dates
Study Start
December 1, 2011
Primary Completion (Actual)
February 1, 2013
Study Completion (Actual)
July 1, 2013
Study Registration Dates
First Submitted
December 15, 2010
First Submitted That Met QC Criteria
December 21, 2010
First Posted (Estimate)
December 23, 2010
Study Record Updates
Last Update Posted (Estimate)
February 10, 2015
Last Update Submitted That Met QC Criteria
February 2, 2015
Last Verified
February 1, 2015
More Information
Terms related to this study
Additional Relevant MeSH Terms
Other Study ID Numbers
- UTHSC-13
This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.
Clinical Trials on Migraine
-
Austrian Migraine Registry CollaborationMedical University of Vienna; Medical University Innsbruck; Austrian Headache...RecruitingMigraine | Chronic Migraine | Migraine Without Aura | Migraine With Aura | Episodic MigraineAustria
-
Tonix Pharmaceuticals, Inc.PremierCompletedChronic Migraine | Chronic Migraine, Headache | Chronic Migraine Without Aura | Aura MigraineUnited States
-
Harvard University Faculty of MedicineBrigham and Women's Hospital; Palmer Center for Chiropractic Research (PCCR)CompletedMigraine | Migraine Disorders | Migraine Without Aura | Migraine With Aura | Migraine, ClassicUnited States
-
University of FlorenceAzienda Ospedaliera Città della Salute e della Scienza di Torino; University... and other collaboratorsRecruitingMigraine | Chronic Migraine | Migraine Without Aura | Migraine With AuraItaly
-
CoolTech LLCTerminatedMigraine | Migraine Without Aura | Migraine With Aura | Episodic MigraineUnited States
-
University of FlorenceAzienda Ospedaliera Città della Salute e della Scienza di Torino; University... and other collaboratorsRecruitingMigraine | Chronic Migraine | Migraine Without Aura | Migraine With AuraItaly
-
Notre-Dame Hospital, Montreal, Quebec, CanadaAllerganCompletedChronic Migraine | Migraine Without Aura | Migraine With AuraCanada
-
Glostrup University Hospital, CopenhagenUnknownChronic Migraine | Migraine Without Aura | Migraine With AuraDenmark
-
Fondazione I.R.C.C.S. Istituto Neurologico Carlo...CompletedMigraine With Aura | Migraine in ChildrenItaly
-
The Cleveland ClinicWithdrawnMigraine | Migraine Disorders | Headache Disorders, Primary | Migraine Headache | Migraine Without Aura | Migraine With Aura | Headache, MigraineUnited States
Clinical Trials on Cranial Electrostimulator
-
University of Campinas, BrazilNot yet recruitingSubacromial Impingement Syndrome | Rotator Cuff Tendinitis | Rotator Cuff Impingement Syndrome
-
University College, LondonCompletedHead and Neck Neoplasms | Xerostomia
-
Touro University NevadaCompleted
-
Oregon Health and Science UniversityCompleted
-
Nova Southeastern UniversityOsteopathic Heritage FoundationsCompletedVisual FunctionUnited States
-
Tufts UniversityRecruitingAnxiety | Cognitive DeficitUnited States
-
European School of OsteopathyUnknown
-
University of Texas Southwestern Medical CenterChildren's HealthRecruitingTorticollis | Congenital Muscular Torticollis | Brachycephaly | Deformational Plagiocephaly | Deformational Posterior PlagiocephalyUnited States
-
University of Texas Southwestern Medical CenterTerminatedSleep Disorder | Cerebrovascular AccidentUnited States
-
Radiation Therapy Oncology GroupNational Cancer Institute (NCI)CompletedLung CancerUnited States, Canada